How a Drug Maker Profited by Slow-Walking a Promising H.I.V. Therapy

treatments, both of which were underpinned by a version of a drug called tenofovir. The promising drug, then in the early stages of testing, was an updated version of tenofovir. Gilead could switch patients to its new drug just before cheap generics hit the market. They denied that the company halted the drug’s development to increase profits. The post How a Drug Maker Profited by Slow-Walking a Promising H.I.V.